Drugs for Vitreous Detachment (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 23)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Midazolam |
Approved, Illicit |
Phase 4 |
|
59467-70-8 |
4192 |
Synonyms:
4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate
59467-70-8
8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride
8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine
AC-18749
AC1L1HMA
BIDD:GT0647
BRN 0625572
Buccolam
C07524
C18H13ClFN3
CHEMBL655
CID4192
D00550
Dazolam
DB00683
Dea no. 2884
Dea No. 2884
DEA No. 2884
Dormicum
Dormicum (TN)
EINECS 261-774-5
Hydrochloride, midazolam
|
LS-77780
Maleate, midazolam
Mezolam
Midanium
midazolam
Midazolam
Midazolam (JAN/INN)
Midazolam [INN:BAN:JAN]
Midazolam base
Midazolam Base
Midazolam Hcl
Midazolam hydrochloride
Midazolam maleate
Midazolamum
Midazolamum [INN-Latin]
Midosed
MolPort-003-849-219
NCGC00168254-01
nchembio747-comp32
Ro 21-3981
TL8003787
UC429_SIGMA
UNII-R60L0SM5BC
Versed
ZINC00001732
|
|
2 |
|
Lidocaine |
Approved, Vet_approved |
Phase 4 |
|
137-58-6 |
3676 |
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
a-Diethylamino-2,6-dimethylacetanilide
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
AKOS001026768
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
Alphacaine
alpha-diethylamino-2,6-dimethylacetanilide
alpha-Diethylamino-2,6-dimethylacetanilide
Anestacon
Anestacon Jelly
ARONIS23855
Astrazeneca brand OF lidocaine
BIDD:GT0342
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
C07073
C14H22N2O
Cappicaine
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
Cito optadren
CPD000058189
Cuivasil
D00358
Dalcaine
DB00281
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jenapharm brand OF lidocanine hydrochloride
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L0156
L1026_SIGMA
L7757_SIGMA
Lanabiotic
L-Caine
Leostesin
Lida-Mantle
Lidocaina
|
Lidocaína
Lidocaina [INN-Spanish]
lidocaine
Lidocaine
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine [USAN:INN:JAN]
Lidocaine carbonate
Lidocaine Carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine Hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
Lidocaine Monohydrochloride
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
LIDOPEN
Lignocaine
Lignocainum
Lingocaine
Lopac0_000669
Lopac-L-5647
LQZ
LS-805
Maricaine
Maybridge1_002571
MLS000069724
MLS000758263
MLS001074177
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
nchembio.65-comp16
NINDS_000174
Norwood Sunburn Spray
Novocol brand OF lidocaine hydrochloride
NSC 40030
NSC40030
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
Solarcaine aloe extra burn relief cream
Solcain
SPBio_001525
SPBio_002100
Spectrum_001118
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
STK552033
Strathmann brand OF lidocaine hydrochloride
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
α-diethylamino-2,6-dimethylacetanilide
Α-diethylamino-2,6-dimethylacetanilide
|
|
3 |
|
Fentanyl |
Approved, Illicit, Investigational, Vet_approved |
Phase 4 |
|
437-38-7 |
3345 |
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-phenethyl-4-N-propionylanilinopiperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
Cephalon brand OF fentanyl buccal oravescent
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
fentanyl
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl [INN:BAN]
Fentanyl CII
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
Fentanyl-50
|
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
Fentora
HSDB 3329
IONSYS
Janssen pharmaceutica brand OF fentanyl
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
Nasalfent
NCGC00168252-01
N-phenethyl-4-(N-propionylanilino)piperidine
N-Phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Subsys
Transmucosal oral fentanyl citrate
UNII-UF599785JZ
|
|
4 |
|
Triazolam |
Approved, Investigational |
Phase 4 |
|
28911-01-5 |
5556 |
Synonyms:
28911-01-5
8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine
8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine
8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine
8-Chloro-6-[2-chlorophenyl]-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
AC1L1KLZ
Alti-Triazolam
Apo triazo
Apo Triazo
Apotex brand OF triazolam
Apotex Brand of Triazolam
Apo-triazo
Apo-Triazo
BRN 1226643
C17H12Cl2N4
CCRIS 1932
CHEBI:9674
CHEMBL646
CID5556
Clorazolam
D00387
D014229
DB00897
DEA no. 2887
DEA No. 2887
EINECS 249-307-3
Gen triazolam
Gen Triazolam
Genpharm brand OF triazolam
Genpharm Brand of Triazolam
Gen-triazolam
Gen-Triazolam
Gerard brand OF triazolam
Gerard Brand of Triazolam
|
Halcion
Halcion (TN)
Halcion (triazolam)
HSDB 6759
Hypnostat
L000796
LS-156323
MolPort-003-959-834
NCGC00168258-01
nchembio747-comp15
Novidorm
Novodorm
Novo-Triolam
Pfizer brand OF triazolam
Pfizer Brand of Triazolam
Songar
T9772_SIGMA
TGAR01H
triazolam
Triazolam
Triazolam (JAN/USP/INN)
Triazolam [USAN:BAN:INN:JAN]
Triazolam pfizer brand
Triazolam Pfizer Brand
Triazolamum
Triazolamum [INN-Latin]
Trilam
U 33,030
U 33030
U33,030
U-33,030
U-33030
UNII-1HM943223R
ZINC00002212
|
|
5 |
|
Propofol |
Approved, Investigational, Vet_approved |
Phase 4 |
|
2078-54-8 |
4943 |
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-bis(1-methylethyl)phenol
2,6-bis(1-methylethyl)-phenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-di(propan-2-yl)phenol
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-DIISOPROPYLPHENOL
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
Abbott brand OF propofol
Abbott Brand of Propofol
AC1L1J9Y
AC1Q1OUI
AC-2038
AI3-26295
Alpha Brand of Propofol
Alpha Brand OF propofol
AM-149
Ampofol
Aquafol
Astra brand OF propofol
Astra Brand of Propofol
AstraZeneca brand OF propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
Biomol-NT_000248
BPBio1_000950
BPBio1_000969
Braun brand OF propofol
Braun Brand of Propofol
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD000059151
CPD-11437
Curamed brand OF propofol
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius brand OF propofol
Fresenius Brand of Propofol
Fresenius kabi brand OF propofol
Fresenius Kabi Brand of Propofol
Fresofol
ghl.PD_Mitscher_leg0.558
HMS1570L04
HMS2089O21
HMS2094E17
HSDB 7123
|
ICI 35,868
ICI 35868
ICI35,868
ICI-35,868
ICI35868
ICI-35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste brand OF propofol
Juste Brand of Propofol
Lopac0_000437
Lopac-D126608
LS-996
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
nchembio.552-comp7
NSC 5105
NSC5105
Parnell brand OF propofol
Parnell Brand of Propofol
PFL
Pisa brand OF propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
propofol
Propofol
Propofol (JAN/USAN/INN)
Propofol [USAN:INN:BAN]
Propofol abbott
Propofol Abbott
Propofol fresenius
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol rovi
Propofol Rovi
Propofol(2,6-Diisopropylphenol)
Propofol-lipuro
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi brand OF propofol
Rovi Brand of Propofol
S01-0189
SAM002264610
Schering brand OF propofol
Schering Brand of Propofol
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
Zeneca brand OF propofol
Zeneca Brand of Propofol
ZINC00968303
|
|
6 |
|
Bupivacaine |
Approved, Investigational |
Phase 4 |
|
38396-39-3, 2180-92-9 |
2474 |
Synonyms:
( inverted exclamation markA)-bupivacaine
(+-)-Bupivacaine
(±)-bupivacaine
(1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
(RS)-bupivacaine
15233-43-9
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
2180-92-9
38396-39-3
AB00053674
Abbott brand OF bupivacaine hydrochloride
AC1L1DRE
AC1Q5LX4
AC-2096
AH 250
AKOS001637202
Anekain
Anhydrous, bupivacaine
AR-1A0242
Astra brand OF bupivacaine hydrochloride
AstraZeneca brand OF bupivacaine hydrochloride
Aventis brand OF bupivacaine hydrochloride
Bio-0886
Bloqueina
BPBio1_000298
Braun brand OF bupivacaine hydrochloride
Braun, bupivacaina
BRD-A01636364-003-05-2
BSPBio_000270
BSPBio_002607
Bucaine
Bucaine (TN)
Bupivacain janapharm
Bupivacain RPR
Bupivacaina
Bupivacaina [INN-Spanish]
Bupivacaina braun
bupivacaine
Bupivacaine
Bupivacaine (INN)
Bupivacaine [INN:BAN]
Bupivacaine anhydrous
Bupivacaine carbonate
Bupivacaine Carbonate
Bupivacaine HCL
Bupivacaine HCL kit
Bupivacaine HCL KIT
Bupivacaine hydrochloride
Bupivacaine monohydrochloride, monohydrate
Bupivacaine Monohydrochloride, Monohydrate
Bupivacain-RPR
Bupivacainum
Bupivacainum [INN-Latin]
Bupivan
Buvacaina
C07529
C18H28N2O
Carbonate, bupivacaine
Carbostesin
cBupivacaine
CBupivacaine
CHEBI:3215
CHEMBL1098
|
CID2474
D07552
DB00297
DepoBupivacaine
DivK1c_000758
dl-1-Butyl-2',6'-pipecoloxylidide
DL-Bupivacaine
Dolanaest
DUR-843
EINECS 218-553-3
EINECS 253-911-2
Exparel
HMS2090F12
Hydrochloride, bupivacaine
IDI1_000758
Inibsa brand OF bupivacaine hydrochloride
Janapharm, bupivacain
Jenapharm brand OF bupivacaine hydrochloride
KBio1_000758
KBio2_002004
KBio2_004572
KBio2_007140
KBio3_001827
KBioGR_001516
KBioSS_002004
KST-1A4609
L000695
LAC-43
LS-109841
LS-2222
Marcain
Marcaina
Marcaine
Marcaine HCL
Marcaine Spinal
MLS001361336
MolPort-004-955-820
NCGC00178579-01
NCGC00178579-02
NINDS_000758
NSC119660
Pisa brand OF bupivacaine hydrochloride
Prestwick0_000305
Prestwick1_000305
Prestwick2_000305
Prestwick3_000305
Racemic bupivacaine
Sensorcaine
Sensorcaine-MPF
Sensorcaine-MPF Spinal
SMR000058218
SPBio_001558
SPBio_002489
Spectrum_001524
Spectrum2_001589
Spectrum3_000974
Spectrum4_001098
Spectrum5_001483
Strathmann brand OF bupivacaine hydrochloride
Svedocain sin vasoconstr
Transdur-Bupivacaine
UNII-Y8335394RO
Win 11318
Win 11318 HCl
|
|
7 |
|
Proxymetacaine |
|
Phase 4 |
|
|
|
8 |
|
Anesthetics |
|
Phase 4 |
|
|
|
9 |
|
Hypnotics and Sedatives |
|
Phase 4 |
|
|
|
10 |
|
Ranibizumab |
Approved |
Phase 2 |
|
347396-82-1 |
459903 |
Synonyms:
347396-82-1
D05697
Lucentis
Lucentis (TN)
ranibizumab
|
Ranibizumab
Ranibizumab (genetical recombination)
Ranibizumab (genetical recombination) (JAN)
Ranibizumab (USAN/INN)
rhuFab V2
|
|
11 |
|
Fibrinolysin |
Investigational |
Phase 2 |
|
9004-09-5 |
|
Synonyms:
Bovine Fibrinolysin
Bovine Plasmin
Fibrinolysin (human)
Fibrinolysin, human
|
Plasmin (bos taurus)
Plasmin (bovine)
Plasmin bovine
|
|
12 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
13 |
|
Plasminogen |
|
Phase 2 |
|
|
|
14 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
15 |
|
Fibrinolytic Agents |
|
Phase 2 |
|
|
|
16 |
|
Dipivefrin |
Approved |
|
|
52365-63-6 |
3105 |
Synonyms:
( -)-2,2-Dimethylpropansaeure-4-(1-hydroxy-2-(methylamino)ethyl)-1,2-phenylenester
( -)-4-(1-Hydroxy-2-methylaminoethyl)-o-phenylendipivalat
(+-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol 3,4-dipivalate
(+-)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate
(+-)-4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalate
(+-)-4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalic acid
(±)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate
(RS)-4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat
[2-(2,2-dimethylpropanoyloxy)-4-[1-hydroxy-2-(methylamino)ethyl]phenyl] 2,2-dimethylpropanoate
1-(3',4'-dipivaloyloxyphenyl)-2-methylamino-1-ethanol
1-(3',4'-Dipivaloyloxyphenyl)-2-methylamino-1-ethanol
2,2-Dimethylpropanoic acid 4-[1-hydroxy-2-(methylamino)ethyl]-1,2-phenylene ester
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat
4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diyl bis(2,2-dimethylpropanoate)
4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate
4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalate
4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalic acid
52365-63-6
AB00514686
AC1L1F6K
Adrenaline dipivalate
AKOS003662293
AKPro
Alcon brand OF dipivefrin hydrochloride
Allergan brand OF dipivefrin hydrochloride
Apo-dipivefrin
Apotex brand OF dipivefrin hydrochloride
BPBio1_000688
BRD-A47494775-003-03-0
BSPBio_000624
C06963
C19H29NO5
CHEBI:4646
CID3105
D Epifrin
D02349
DB00449
Diopine
Dipivaloylepinephrine
dipivalyl epinephrine
Dipivalyl epinephrine
dipivefrin
Dipivefrin
Dipivefrin (USAN)
|
Dipivefrin [USAN]
Dipivefrin acetate, (+-)-isomer
Dipivefrin citrate (1:1), (+-)-isomer
Dipivefrin HCL
Dipivefrin hydrochloride
Dipivefrin hydrochloride, (+-)-isomer
Dipivefrin monophosphate, (+-)-isomer
Dipivefrin monosulfate, (+-)-isomer
Dipivefrin nitrate, (+-)-isomer
Dipivefrin perchlorate
Dipivefrin propanoate, (+-)-isomer
Dipivefrin tartrate (1:1), (+-)-(R-(r*,r*))-isomer
Dipivefrin tartrate (1:1), (R)-(R-(r*,r*))-isomer
Dipivefrin, (R)-isomer
Dipivefrina
Dipivefrina [INN-Spanish]
Dipivefrine
Dipivéfrine
Dipivefrine (INN)
Dipivefrinum
Dipivefrinum [INN-Latin]
Dipoquin
Glaucothil
Glaudrops
Ioquin brand OF dipivefrin hydrochloride
K 30081
L000915
LS-121419
NCGC00179499-01
nchembio747-comp3
Ophtho-Dipivefrin
Pharm-allergan brand OF dipivefrin hydrochloride
Pharmascience brand OF dipivefrin hydrochloride
PMS-Dipivefrin
Prestwick0_000632
Prestwick1_000632
Prestwick2_000632
Prestwick3_000632
Propine
Propine C Cap B.I.D.
Ratio-dipivefrin
Ratiopharm brand OF dipivefrin hydrochloride
SPBio_002843
UNII-8Q1PVL543G
|
|
17 |
|
Triamcinolone |
Approved, Vet_approved |
|
|
124-94-7 |
31307 |
Synonyms:
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11b,16a,17a,21-Tetrahydroxy-9a-fluoro-1,4-pregnadiene-3,20-dione
11beta,16alpha,17alpha,21-Tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dione
11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione
11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
11Β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
124-94-7
4-08-00-03629 (Beilstein Handbook Reference)
83474-03-7
9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d
9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone
9a-Fluoro-11b,16a,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9a-Fluoro-11b,16a,17a,21-tetrahydroxypregna-1,4-diene-3,20-dione
9a-Fluoro-16a-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9-alpha-Fluoro-16-alpha-hydroxyprednisolone
9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11b,16a,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-16α-hydroxyprednisolone
9Α-fluoro-16α-hydroxyprednisolone
AC1L1LDH
AC1Q5HJC
AC-2072
Adcortyl
Aristocort
Aristocort A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
Bio-0662
BPBio1_000154
BRD-K77554836-001-03-3
BRN 2341955
BSPBio_000140
C21H27FO6
Celeste
CHEMBL1451
CID31307
Cinolone
Cinolone-T
CL 19823
D00385
D014221
DB00620
Delphicort
droxypregna-1,4-diene-3,20-dione
EINECS 204-718-7
EU-0101179
Fluoxiprednisolone
Fluoxyprednisolone
Flutex
Fougera
HMS1568G22
HMS2090D12
HSDB 3194
ione
Kenacort
Kenacort (TN)
Kenacort-A
Kenacort-Ag
Kenacort-AG
Kenalog
|
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
Ledercort
Lopac0_001179
LS-698
MLS000028542
MLS001066543
MLS002695935
MolPort-002-528-981
Mycolog
Nasacort
Nasacort Aq
Nasacort Hfa
NCGC00021580-03
NCGC00021580-04
NCGC00021580-05
NCGC00021580-06
NCGC00021580-07
nchembio.2007.53-comp7
NCI60_000750
NSC 13397
NSC13397
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Pregna-1,4-diene-3,20-dio
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI)
Prestwick_438
Prestwick0_000120
Prestwick1_000120
Prestwick2_000120
Prestwick3_000120
Rodinolone
S1933_Selleck
Sk-Triamcinolone
SK-Triamcinolone
SMP1_000300
SMR000058333
SPBio_002079
T6376_SIGMA
Tiamcinolonum
Tiamcinolonum [INN-Latin]
Triacet
Triacort
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
triamcinolone
Triamcinolone
Triamcinolone (JP15/USP/INN)
TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7))
Triamcinolone [USAN:INN:BAN:JAN]
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triam-Tablinen
Triatex
Tricortale
Triderm
Trilone
Tri-Nasal
Tristoject
Trymex
UNII-1ZK20VI6TY
Vetalog
Volon
Volon A
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ
ZINC03882036
|
|
18 |
|
Bevacizumab |
Approved, Investigational |
|
|
216974-75-3 |
|
Synonyms:
216974-75-3
antiVEGF
Anti-VEGF Humanized Monoclonal Antibody
anti-VEGF monoclonal antibody
Anti-VEGF monoclonal antibody
Avastin
Avastin (TN)
bevacizumab
|
Bevacizumab
Bevacizumab (genetical recombination)
Bevacizumab (genetical recombination) (JAN)
bevacizumab-awwb
D06409
R-435
rhuMAb-VEGF
|
|
19 |
|
triamcinolone acetonide |
|
|
|
|
|
20 |
|
Triamcinolone hexacetonide |
|
|
|
|
|
21 |
|
Triamcinolone diacetate |
|
|
|
|
|
22 |
|
Antineoplastic Agents, Immunological |
|
|
|
|
|
23 |
|
Tissue Plasminogen Activator |
|
|
|
|
|
Interventional clinical trials:
(show all 28)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Comparative Analysis of Oral Sedation Versus Standard Intravenous Sedation in Vitreoretinal Surgery With Topical Anesthesia and Sub-tenon's Block |
Not yet recruiting |
NCT04346095 |
Phase 4 |
Oral Sedatives with or Without Analgesia;Intravenous Sedatives with or Without Analgesia |
2 |
A Phase 3 Safety and Efficacy Study of Vitreosolve® for Four Ophthalmic Intravitreal Injections For Inducing Posterior Vitreous Detachment in Retinopathy Patients. |
Unknown status |
NCT00908778 |
Phase 3 |
Vitreosolve;Vitreosolve |
3 |
An Open-label Assessment of Intravitreous Injections of Vitrase (Hyaluronidase for Injection) for Inducing Posterior Vitreous Detachment in Subjects With Moderate to Severe Non-proliferative Diabetic Retinopathy |
Completed |
NCT00198471 |
Phase 2 |
Vitrase |
4 |
A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical Posterior Vitreous Detachment (PVD) Induction for Treatment of Vitreomacular Traction (VMT). |
Completed |
NCT00435539 |
Phase 2 |
ocriplasmin;ocriplasmin;Sham Comparator |
5 |
A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical Posterior Vitreous Detachment (PVD) Induction for Treatment of DME. |
Completed |
NCT00412451 |
Phase 2 |
ocriplasmin |
6 |
Posterior Vitreous Detachment (PVD) Assessment During Dual RVO Lucentis Evaluations (PADDLE Study) |
Completed |
NCT00831350 |
Phase 2 |
Ranibizumab |
7 |
A Phase 2, Randomised, Double Masked, Sham Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total Posterior Vitreous Detachment (PVD) in Subjects With Non-proliferative Diabetic Retinopathy (NPDR) |
Terminated |
NCT02681809 |
Phase 2 |
ocriplasmin 0.0625mg;ocriplasmin 0.125mg;Sham injection |
8 |
A Multicenter, Randomized, Double Masked, Placebo Controlled, Sequential Dose Response Study of Intravitreally Administered Plasmin for the Creation of a Posterior Vitreous Detachment (PVD) |
Terminated |
NCT00348439 |
Phase 2 |
Plasmin;Vehicle |
9 |
An Open Label Sequential Dose Response Observational Study of Intravitreally Administered Plasmin for the Creation of a Posterior Vitreous Detachment (PVD) |
Terminated |
NCT00347646 |
Phase 1, Phase 2 |
Plasmin |
10 |
Partial Posterior Hyaloidectomy in Macular Surgery : A Modified Procedure of Vitrectomy to Prevent Retinal Break Related to Induction of a Posterior Vitreous Detachment |
Completed |
NCT01454466 |
Phase 1 |
|
11 |
Vitreopapillary Traction and Optic Disc Morphology in Healthy Subjects, Vitreomacular Traction Patients and Glaucoma Patients |
Unknown status |
NCT02290795 |
|
|
12 |
Vitrectomy Without Laser or Gas Tamponade for Optic Disc Pit Maculopathy |
Completed |
NCT01340703 |
|
|
13 |
Assessment of Retinal Layers and Visual Rehabilitation After Epiretinal Membrane Removal |
Completed |
NCT01474655 |
|
|
14 |
High-frequency-ultrasound Annular Arrays for Ophthalmic Imaging |
Completed |
NCT01415037 |
|
|
15 |
Randomized Trial of Laser Ablation for Highly Symptomatic Floaters |
Completed |
NCT01970267 |
|
|
16 |
High-frequency-ultrasound Annular Arrays for Small Animal and Ophthalmic Imaging |
Completed |
NCT00633854 |
|
|
17 |
Intravitreal Administration of Ranibizumab Combined With Intravitreous Injection of Expansile Gas and Induction of Posterior Vitreous Detachment in Treatment of Exudative AMD With Posterior VMA: a Pilot, Open Label, Comparative Study |
Completed |
NCT01291121 |
|
|
18 |
A Prospective Randomized Controlled Trial Evaluating the Safety and Efficacy of YAG Vitreolysis Versus Sham for Symptomatic Weiss Ring Due to Posterior Vitreous Detachment |
Completed |
NCT02897583 |
|
|
19 |
Vitrectomy for Persistent Macular Edema in Branch Retinal Vein Occlusion |
Completed |
NCT00685490 |
|
|
20 |
Outcomes of Vitrectomy in Pediatric Retinal Detachment With Proliferative Vitreoretinopathy |
Completed |
NCT03208205 |
|
|
21 |
Comparison of a Spectral OCT/SLO With the Stratus OCT for Imaging Various Retinal Pathologies |
Completed |
NCT00408720 |
|
|
22 |
Influence of Posterior Vitreous Detachment on Retinal Detachment After Lens Surgery in Myopic Eyes |
Recruiting |
NCT03152747 |
|
|
23 |
Rate of Visual Field Progression Before and After Posterior Vitreous Detachment |
Recruiting |
NCT04719871 |
|
|
24 |
YAG Laser Vitreolysis of Symptomatic Vitreal Floaters |
Recruiting |
NCT03970148 |
|
|
25 |
The Incidence of Complete Posterior Vitreous Degeneration After Phacoemulsification |
Not yet recruiting |
NCT04727398 |
|
|
26 |
Incidence of Complete Posterior Vitreous Detachment After Trabeculectomy. |
Not yet recruiting |
NCT04726267 |
|
|
27 |
Evaluation of the Role of Intravitreal Injection of TPA in Treatment of Refractory Diabetic Macular Edema |
Terminated |
NCT01141881 |
|
Tissue Plasminogen Activator,bevacizumab ,follow up |
28 |
Effect on the Vitreous of the Not Complicated Surgery of the Cataract to the Emmetropic Patient |
Terminated |
NCT02783209 |
|
|
|